Search

Coloplast A-S (Class B)

Fechado

569.8 -0.9

Visão Geral

Variação de preço das ações

24h

Atual

Mín

564.4

Máximo

579.4

Indicadores-chave

By Trading Economics

Rendimento

70M

875M

Vendas

2M

7B

P/E

Médio do Setor

35.807

90.831

EPS

3.88

Rendimento de Dividendos

4.01

Margem de lucro

12.572

Funcionários

16,744

EBITDA

2B

Recomendações

By TipRanks

Recomendações

Neutro

Previsão para 12 meses

+11.86% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

4.01%

2.20%

Próximos Ganhos

6 de fev. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

7.5B

130B

Abertura anterior

570.7

Fecho anterior

569.8

Coloplast A-S (Class B) Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

14 de jan. de 2026, 22:41 UTC

Aquisições, Fusões, Aquisições de Empresas

Canadian Natural Resources, Tourmaline File Deal Notice With Antitrust Regulator

15 de jan. de 2026, 00:00 UTC

Ganhos

Welcome to Greenland, an Economy Reliant on Subsidies and Shrimp -- WSJ

14 de jan. de 2026, 23:47 UTC

Conversa de Mercado

Oil Slips After Trump Appears to Tilt Away From Military Action in Iran -- Market Talk

14 de jan. de 2026, 23:44 UTC

Conversa de Mercado

Nikkei May Decline After Hitting Record Highs; Election in Focus -- Market Talk

14 de jan. de 2026, 23:39 UTC

Conversa de Mercado

ANZ's New Bull Still Sees Valuation Gap to Peers -- Market Talk

14 de jan. de 2026, 23:32 UTC

Conversa de Mercado

Gold Declines on Likely Technical Correction, Possible Profit-Taking -- Market Talk

14 de jan. de 2026, 22:56 UTC

Aquisições, Fusões, Aquisições de Empresas

Soho House Amends Rollover and Support Agreements With Broad Street Principal Investments and Others

14 de jan. de 2026, 22:53 UTC

Aquisições, Fusões, Aquisições de Empresas

Soho House: Apollo Global Management and Goldman Sachs Asset Management Amend Debt Commitment

14 de jan. de 2026, 22:17 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

14 de jan. de 2026, 22:17 UTC

Conversa de Mercado

WiseTech's Revenue Growth Drivers Attract Scrutiny -- Market Talk

14 de jan. de 2026, 22:09 UTC

Ganhos

CITIC Securities: Uptrend in China Capital Markets Supported Results >600030.SH

14 de jan. de 2026, 22:08 UTC

Ganhos

CITIC Securities 2025 Oper Rev CNY74.83B Vs. CNY58.12B >600030.SH

14 de jan. de 2026, 22:08 UTC

Ganhos

CITIC Securities 2025 Net CNY30.05B Vs. Net CNY21.57B >600030.SH

14 de jan. de 2026, 21:53 UTC

Aquisições, Fusões, Aquisições de Empresas

WuXi XDC Expects 2025 Net to Increase Over 38% on Year

14 de jan. de 2026, 21:53 UTC

Aquisições, Fusões, Aquisições de Empresas

WuXi XDC Expects 2025 Revenue to Increase More Than 45% on Year

14 de jan. de 2026, 21:52 UTC

Aquisições, Fusões, Aquisições de Empresas

WuXi XDC Announces Positive Profit Alert for 2025

14 de jan. de 2026, 21:51 UTC

Aquisições, Fusões, Aquisições de Empresas

Citigroup Acting as Financial Advisor to WuXi XDC

14 de jan. de 2026, 21:51 UTC

Aquisições, Fusões, Aquisições de Empresas

WuXi XDC: Aims to Keep Listing Status of BioDlink

14 de jan. de 2026, 21:51 UTC

Aquisições, Fusões, Aquisições de Empresas

WuXi XDC: Company to Finance BioDlink Shares Acquisition via Internal Resources

14 de jan. de 2026, 21:50 UTC

Conversa de Mercado
Ganhos

Financial Services Roundup: Market Talk

14 de jan. de 2026, 21:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

14 de jan. de 2026, 21:49 UTC

Aquisições, Fusões, Aquisições de Empresas

WuXi XDC: BioDlink Offer to Cost HK$2.79B

14 de jan. de 2026, 21:48 UTC

Aquisições, Fusões, Aquisições de Empresas

WuXi XDC Offers to Pay HK$4.00 for Each BioDlink International Share

14 de jan. de 2026, 21:48 UTC

Aquisições, Fusões, Aquisições de Empresas

WuXi XDC Makes Cash Offer for BioDlink International

14 de jan. de 2026, 21:13 UTC

Conversa de Mercado

Oil Retreats Late After Trump Comments on Iran -- Market Talk

14 de jan. de 2026, 20:30 UTC

Conversa de Mercado
Ganhos

Danaher's Preliminary 4Q Seen as Promising -- Market Talk

14 de jan. de 2026, 20:13 UTC

Conversa de Mercado

U.S. Natural Gas Futures Sink Ahead of Storage Report -- Market Talk

14 de jan. de 2026, 20:08 UTC

Conversa de Mercado

Oil Futures Extend Rally on Iran Tensions -- Market Talk

14 de jan. de 2026, 19:33 UTC

Conversa de Mercado

Nutrien Seen as Winner in Tighter 2026 Potash Market, Higher Prices -- Market Talk

14 de jan. de 2026, 19:06 UTC

Conversa de Mercado
Ganhos

Wells Fargo Says Customers, Economy Remain Resilient -- Market Talk

Coloplast A-S (Class B) Previsão

Preço-alvo

By TipRanks

11.86% parte superior

Previsão para 12 meses

Média 901.38 DKK  11.86%

Máximo 1,056 DKK

Mínimo 720 DKK

Com base em 8 analistas de Wall Street que oferecem metas de preço de 12 meses para Coloplast A-S (Class B) - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

8 ratings

2

Comprar

4

Manter

2

Vender

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Coloplast A-S (Class B)

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.
help-icon Live chat